## HOUSE BILL 2967

State of Washington

66th Legislature

2020 Regular Session

By Representative Macri

- 1 AN ACT Relating to the prescriptive authority of psychologists; 2 amending RCW 18.83.010, 18.83.050, 18.83.080, and 18.83.090; 3 reenacting and amending RCW 18.64.011, 18.79.260, and 69.50.101; and
- adding new sections to chapter 18.83 RCW. 4
- 5 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:
- 6 Sec. 1. RCW 18.83.010 and 1994 c 35 s 1 are each amended to read 7 as follows:
- ((When used in this chapter:)) The definitions in this section 8 apply throughout this chapter unless the context clearly requires 9 10 otherwise.
  - (1) ((The)) "Board" means the examining board of psychology.
- (2) "Clinical experience" means a period of supervised clinical 12 training and practice in which clinical diagnoses and interventions 13 are learned and which is conducted and supervised as part of the 14 15 training program.
- (3) "Controlled substance" has the same meaning as in RCW 16 17 69.50.101.
- 18 (4) "Department" means the department of health.
- 19 (5) "Practice of psychology" means the observation, evaluation, 20 interpretation, and modification of human behavior by the application 21 of psychological principles, methods, and procedures for the purposes

HB 2967 p. 1

- of preventing or eliminating symptomatic or maladaptive behavior and promoting mental and behavioral health. It includes, but is not limited to, providing the following services to individuals, families, groups, organizations, and the public, whether or not payment is received for services rendered:
- 6 (a) Psychological measurement, assessment, and evaluation by 7 means of psychological, neuropsychological, and psychoeducational 8 testing;
- 9 (b) Diagnosis and treatment of mental, emotional, and behavioral 10 disorders, and psychological aspects of illness, injury, and 11 disability; and

13

14 15

16

17

18 19

2021

2223

24

25

2627

28

2930

31

32

33 34

3536

37

(c) Counseling and guidance, psychotherapeutic techniques, remediation, health promotion, and consultation within the context of established psychological principles and theories.

This definition does not include the teaching of principles of psychology for accredited educational institutions, or the conduct of research in problems of human or animal behavior.

- ((Nothing in this definition shall be construed as permitting the administration or prescribing of drugs or in any way infringing upon the practice of medicine and surgery as defined in chapter 18.71 RCW.
- (2))) (6) "Prescribing psychologist" means a person who holds an active license to practice psychology under this chapter and holds an active certificate to exercise prescriptive authority under the standards of section 2 of this act.
  - (7) "Prescription" has the same meaning as in RCW 18.64.011.
- (8) "Prescriptive authority" means the authority of a prescribing psychologist to prescribe, administer, discontinue, and distribute controlled substances recognized or customarily used in the diagnosis, treatment, and management of individuals with psychiatric, mental, cognitive, nervous, emotional, developmental, or behavioral disorders. The term includes ordering necessary laboratory tests and diagnostic examinations, procedures necessary to obtain laboratory tests and diagnostic examinations, procedures which are relevant to the practice of psychology, and other directly related procedures within the scope of the practice of psychology in accordance with rules adopted by the board.
  - (9) "Secretary" means the secretary of health.
- 38 ((<del>(3)</del> "Board" means the examining board of psychology.
- 39 (4) "Department" means the department of health.))

p. 2 HB 2967

- NEW SECTION. Sec. 2. A new section is added to chapter 18.83
  RCW to read as follows:
  - (1) A psychologist who is licensed under this chapter may apply for certification as a prescribing psychologist to allow the psychologist to exercise prescriptive authority.
  - (2) The board shall certify an applicant as a prescribing psychologist if the applicant demonstrates to the board, by official transcript or other official evidence satisfactory to the board, that the applicant:
    - (a) Holds a current license as a psychologist;
- 11 (b) Holds a doctorate degree obtained from an integrated program of graduate study in psychology, as defined by rules of the board;
- 13 (c)(i) Has successfully completed an organized sequence of study 14 in a master's degree offering intensive didactic education, and 15 including the following core areas of instruction:
  - (A) Basic science;
  - (B) Functional neurosciences;
  - (C) Physical examination;
- 19 (D) Interpretation of laboratory tests;
- 20 (E) Pathological basis of disease;
- 21 (F) Clinical medicine;
- 22 (G) Clinical neurotherapeutics;
- 23 (H) Systems of care;
- 24 (I) Pharmacology;

4

5

7

8

10

16

17

18

- 25 (J) Clinical pharmacology;
- 26 (K) Psychopharmacology;
- 27 (L) Psychopharmacology research; and
- 28 (M) Professional, ethical, and legal issues;
- 29 (ii) The didactic portion of the education must consist of an 30 appropriate number of didactic hours to assure acquisition of the 31 necessary knowledge and skills to prescribe in a safe and effective 32 manner;
- 33 successfully completed a postdoctoral prescribing (d) Has psychology fellowship defined by the board to obtain clinical 34 in 35 experience sufficient to attain competency psychopharmacological treatment of a diverse patient population under 36 37 the direction of qualified practitioners, as determined by the board; 38 and

p. 3 HB 2967

- (e) Has passed an examination relevant to establishing competence for prescribing as developed by a nationally recognized organization and approved by the board.
- 4 (3) The board may waive certain requirements for applicants who bave obtained relevant training and experience including:

7

8

17

18

1920

27

28

29

3031

32

33

34

35

36

- (a) Psychologists who are dually licensed as physicians, nurse practitioners, or another health profession with comparable prescriptive authority in Washington; or
- 9 (b) Psychologists who have completed the United States department 10 of defense psychopharmacology demonstration project.
- 11 (4) A certificate issued under this section may be renewed in accordance with RCW 18.83.090.
- NEW SECTION. Sec. 3. A new section is added to chapter 18.83
  RCW to read as follows:
- 15 (1) Prescribing psychologists may exercise prescriptive authority 16 as provided in this chapter.
  - (2) A psychologist may not exercise prescriptive authority unless the psychologist holds a valid certificate of prescriptive authority under section 2 of this act.
    - (3) Each prescription issued by a prescribing psychologist must:
- 21 (a) Comply with all applicable state and federal laws and 22 regulations; and
- 23 (b) Be identified as written by the prescribing psychologist in a 24 manner determined by the board.
- 25 (4) A record of all prescriptions must be maintained in the 26 patient's record.
  - (5) A prescribing psychologist may not delegate the authority to prescribe drugs and controlled substances to any other person.
  - (6) A prescribing psychologist who is authorized to prescribe controlled substances must submit to the board, in a timely manner, the prescribing psychologist's drug enforcement agency registration number.
  - (7) The board shall maintain a current list of every prescribing psychologist, the psychologists' license and certificate of prescribing authority numbers, and the drug enforcement agency registration and number.
- 37 (8)(a) The board shall transmit to the pharmacy quality assurance 38 commission an initial list of prescribing psychologists. The list 39 must contain:

p. 4 HB 2967

- 1 (i) The name of each prescribing psychologist;
- 2 (ii) Each prescribing psychologist's identification number 3 assigned by the board; and
- 4 (iii) The effective date of each prescribing psychologist's certificate of prescriptive authority.
- 6 (b) The board shall promptly notify the pharmacy quality 7 assurance commission of:
- 8 (i) Any additions to the initial list as new prescribing 9 psychologists are certified; and
- 10 (ii) The termination, suspension, or reinstatement of any 11 prescribing psychologist's certification.
- 12 **Sec. 4.** RCW 18.83.050 and 2004 c 262 s 8 are each amended to 13 read as follows:
- 14 (1) The board shall adopt such rules as it deems necessary to 15 carry out its functions.
  - (2) The board shall examine the qualifications of applicants for licensing under this chapter, to determine which applicants are eligible for licensing under this chapter and shall forward to the secretary the names of applicants so eligible.
- 20 (3) The board shall:

1718

19

24

2526

27

28

29

30

3132

33

34

35

3637

- 21 <u>(a) Develop and implement procedures for reviewing education and</u>
  22 <u>training credentials of applicants for certificates of prescriptive</u>
  23 <u>authority;</u>
  - (b) Certify an applicant as a prescribing psychologist if the applicant meets the qualifications of section 2 of this act; and
  - (c) Adopt rules for denying, modifying, suspending, or revoking certification of a prescribing psychologist. The board may require remediation of any deficiencies in the training or practice pattern of the prescribing psychologist when, in the judgment of the board, such deficiencies could reasonably be expected to jeopardize the health, safety, or welfare of the public.
  - (4) The board shall administer examinations to qualified applicants on at least an annual basis. The board shall determine the subject matter and scope of the examination, except as provided in RCW 18.83.170. The board may allow applicants to take the examination upon the granting of their doctoral degree before completion of their internship for supervised experience.
- $((\frac{(4)}{(4)}))$  (5) The board shall keep a complete record of its own proceedings, of the questions given in examinations, of the names and

p. 5 HB 2967

- qualifications of all applicants, and the names and addresses of all licensed psychologists. The examination paper of such applicant shall be kept on file for a period of at least one year after examination.
  - ((+5+)) (6) The board shall, by rule, adopt a code of ethics for psychologists which is designed to protect the public interest.

5

21

22

23

24

2526

27

2829

30

31

32

33

34

35

36

- 6 ((<del>(6)</del>)) <u>(7)</u> The board may require that persons licensed under 7 this chapter as psychologists obtain and maintain professional 8 liability insurance in amounts determined by the board to be 9 practicable and reasonably available.
- 10 **Sec. 5.** RCW 18.83.080 and 1996 c 191 s 66 are each amended to 11 read as follows:

The board shall forward to the secretary the name of each applicant entitled to a license under this chapter. The secretary shall promptly issue to such applicant a license authorizing such applicant to use the title "psychologist". Each licensed psychologist shall keep his or her license and certificate of prescriptive authority, if applicable, displayed in a conspicuous place in his or her principal place of business.

- 19 **Sec. 6.** RCW 18.83.090 and 2009 c 492 s 6 are each amended to 20 read as follows:
  - (1) The board shall establish rules governing mandatory continuing education requirements which shall be met by any psychologist applying for a license renewal or renewal of a certificate of prescriptive authority.
  - (2) The office of crime victims advocacy shall supply the board with information on methods of recognizing victims of human trafficking, what services are available for these victims, and where to report potential trafficking situations. The information supplied must be culturally sensitive and must include information relating to minor victims. The board shall disseminate this information to licensees by: Providing the information on the board's web site; including the information in newsletters; holding trainings at meetings attended by organization members; or ((through)) another distribution method determined by the board. The board shall report to the office of crime victims advocacy on the method or methods it uses to distribute information under this subsection.

p. 6 HB 2967

- 1 (3) Administrative procedures, administrative requirements, and 2 fees for renewal and reissue of licenses shall be established as 3 provided in RCW 43.70.250 and 43.70.280.
- 4 (4) (a) The board shall establish rules for the renewal of a
  5 certificate of prescriptive authority issued under section 2 of this
  6 act at the time of the renewal of the psychologist's license to
  7 practice psychology.
- 8 (b) Each applicant for renewal of a certificate of prescriptive
  9 authority shall present satisfactory evidence to the board
  10 demonstrating the completion of continuing education instruction
  11 relevant to prescriptive authority during the previous three-year
  12 renewal period.
- Sec. 7. RCW 18.64.011 and 2016 c 148 s 1 are each reenacted and amended to read as follows:
- The definitions in this section apply throughout this chapter unless the context clearly requires otherwise.

19

20

2122

2324

25

26

2728

2930

31

32

33 34

35

- (1) "Administer" means the direct application of a drug or device, whether by injection, inhalation, ingestion, or any other means, to the body of a patient or research subject.
- (2) "Business licensing system" means the mechanism established by chapter 19.02 RCW by which business licenses, endorsed for individual state-issued licenses, are issued and renewed utilizing a business license application and a business license expiration date common to each renewable license endorsement.
- (3) "Chart order" means a lawful order for a drug or device entered on the chart or medical record of an inpatient or resident of an institutional facility by a practitioner or his or her designated agent.
- (4) "Closed door long-term care pharmacy" means a pharmacy that provides pharmaceutical care to a defined and exclusive group of patients who have access to the services of the pharmacy because they are treated by or have an affiliation with a long-term care facility or hospice program, and that is not a retailer of goods to the general public.
  - (5) "Commission" means the pharmacy quality assurance commission.
- 36 (6) "Compounding" means the act of combining two or more 37 ingredients in the preparation of a prescription.

р. 7

- (7) "Controlled substance" means a drug or substance, or an immediate precursor of such drug or substance, so designated under or pursuant to the provisions of chapter 69.50 RCW.
- (8) "Deliver" or "delivery" means the actual, constructive, or attempted transfer from one person to another of a drug or device, whether or not there is an agency relationship.
  - (9) "Department" means the department of health.
- (10) "Device" means instruments, apparatus, and contrivances, including their components, parts, and accessories, intended (a) for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in human beings or other animals, or (b) to affect the structure or any function of the body of human beings or other animals.
- (11) "Dispense" means the interpretation of a prescription or order for a drug, biological, or device and, pursuant to that prescription or order, the proper selection, measuring, compounding, labeling, or packaging necessary to prepare that prescription or order for delivery.
- 19 (12) "Distribute" means the delivery of a drug or device other 20 than by administering or dispensing.
  - (13) "Drug" and "devices" do not include surgical or dental instruments or laboratory materials, gas and oxygen, therapy equipment, X-ray apparatus or therapeutic equipment, their component parts or accessories, or equipment, instruments, apparatus, or contrivances used to render such articles effective in medical, surgical, or dental treatment, or for use or consumption in or for mechanical, industrial, manufacturing, or scientific applications or purposes. "Drug" also does not include any article or mixture covered by the Washington pesticide control act (chapter 15.58 RCW), as enacted or hereafter amended, nor medicated feed intended for and used exclusively as a feed for animals other than human beings.
    - (14) "Drugs" means:

- (a) Articles recognized in the official United States pharmacopoeia or the official homeopathic pharmacopoeia of the United States;
- 36 (b) Substances intended for use in the diagnosis, cure, 37 mitigation, treatment, or prevention of disease in human beings or 38 other animals;
- 39 (c) Substances (other than food) intended to affect the structure 40 or any function of the body of human beings or other animals; or

p. 8 HB 2967

(d) Substances intended for use as a component of any substances specified in (a), (b), or (c) of this subsection, but not including devices or their component parts or accessories.

1

2

3

9

15 16

17

18

19

20 21

22

23

24

25

26

27 28

29

30 31

32

33

34

35 36

37

38 39

40

- (15) "Health care entity" means an organization that provides 4 health care services in a setting that is not otherwise licensed by 5 6 the state to acquire or possess legend drugs. Health care entity 7 includes a freestanding outpatient surgery center, a residential treatment facility, and a freestanding cardiac care center. "Health 8 care entity" does not include an individual practitioner's office or a multipractitioner clinic, regardless of ownership, unless the owner 10 11 elects licensure as a health care entity. "Health care entity" also 12 include an individual practitioner's office or does not multipractitioner clinic identified by a hospital on a pharmacy 13 application or renewal pursuant to RCW 18.64.043. 14
  - (16) "Hospice program" means a hospice program certified or paid by medicare under Title XVIII of the federal social security act, or a hospice program licensed under chapter 70.127 RCW.
  - (17) "Institutional facility" means any organization whose primary purpose is to provide a physical environment for patients to obtain health care services including, but not limited to, services in a hospital, long-term care facility, hospice program, mental health facility, drug abuse treatment center, residential habilitation center, or a local, state, or federal correction facility.
  - (18) "Labeling" means the process of preparing and affixing a label to any drug or device container. The label must include all information required by current federal and state law and pharmacy rules.
  - (19) "Legend drugs" means any drugs which are required by any applicable federal or state law or regulation to be dispensed on prescription only or are restricted to use by practitioners only.
  - (20) "Long-term care facility" means a nursing home licensed under chapter 18.51 RCW, an assisted living facility licensed under chapter 18.20 RCW, or an adult family home licensed under chapter 70.128 RCW.
  - (21) "Manufacture" means the production, preparation, propagation, compounding, or processing of a drug or other substance or device or the packaging or repackaging of such substance or device, or the labeling or relabeling of the commercial container of such substance or device, but does not include the activities of a

p. 9 HB 2967

- 1 practitioner who, as an incident to his or her administration or dispensing such substance or device in the course of his or her 2 professional practice, personally prepares, compounds, packages, or 3 labels such substance or device. "Manufacture" includes the 4 distribution of a licensed pharmacy compounded drug product to other 5 6 state licensed persons or commercial entities for subsequent resale 7 or distribution, unless a specific product item has approval of the commission. The term does not include: 8
  - (a) The activities of a licensed pharmacy that compounds a product on or in anticipation of an order of a licensed practitioner for use in the course of their professional practice to administer to patients, either personally or under their direct supervision;

10 11

12

13

14

1516

17

18

1920

21

22

23

2425

26

27

28

29

30 31

32

33

34

- (b) The practice of a licensed pharmacy when repackaging commercially available medication in small, reasonable quantities for a practitioner legally authorized to prescribe the medication for office use only;
- (c) The distribution of a drug product that has been compounded by a licensed pharmacy to other appropriately licensed entities under common ownership or control of the facility in which the compounding takes place; or
- (d) The delivery of finished and appropriately labeled compounded products dispensed pursuant to a valid prescription to alternate delivery locations, other than the patient's residence, when requested by the patient, or the prescriber to administer to the patient, or to another licensed pharmacy to dispense to the patient.
- (22) "Manufacturer" means a person, corporation, or other entity engaged in the manufacture of drugs or devices.
- (23) "Nonlegend" or "nonprescription" drugs means any drugs which may be lawfully sold without a prescription.
- (24) "Person" means an individual, corporation, government, governmental subdivision or agency, business trust, estate, trust, partnership or association, or any other legal entity.
- (25) "Pharmacist" means a person duly licensed by the commission to engage in the practice of pharmacy.
- 35 (26) "Pharmacy" means every place properly licensed by the 36 commission where the practice of pharmacy is conducted.
- 37 (27) "Poison" does not include any article or mixture covered by 38 the Washington pesticide control act (chapter 15.58 RCW), as enacted 39 or hereafter amended.

p. 10 HB 2967

- 1 (28) "Practice of pharmacy" includes the practice of and responsibility for: Interpreting prescription orders; the 2 3 compounding, dispensing, labeling, administering, and distributing of drugs and devices; the monitoring of drug therapy and use; the 4 initiating or modifying of drug therapy in accordance with written 5 6 guidelines or protocols previously established and approved for his 7 or her practice by a practitioner authorized to prescribe drugs; the participating in drug utilization reviews and drug product selection; 8 the proper and safe storing and distributing of drugs and devices and 9 maintenance of proper records thereof; the providing of information 10 11 on legend drugs which may include, but is not limited to, the 12 advising of therapeutic values, hazards, and the uses of drugs and 13 devices.
  - (29) "Practitioner" means a physician, dentist, veterinarian, nurse, <u>prescribing psychologist</u>, or other person duly authorized by law or rule in the state of Washington to prescribe drugs.

1516

17

1819

20

23

2425

26

27

2829

30 31

- (30) "Prescription" means an order for drugs or devices issued by a practitioner duly authorized by law or rule in the state of Washington to prescribe drugs or devices in the course of his or her professional practice for a legitimate medical purpose.
- 21 (31) "Secretary" means the secretary of health or the secretary's designee.
  - (32) "Shared pharmacy services" means a system that allows a participating pharmacist or pharmacy pursuant to a request from another participating pharmacist or pharmacy to process or fill a prescription or drug order, which may include but is not necessarily limited to preparing, packaging, labeling, data entry, compounding for specific patients, dispensing, performing drug utilization reviews, conducting claims adjudication, obtaining refill authorizations, reviewing therapeutic interventions, or reviewing chart orders.
- 32 (33) "Wholesaler" means a corporation, individual, or other 33 entity which buys drugs or devices for resale and distribution to 34 corporations, individuals, or entities other than consumers.
- 35 **Sec. 8.** RCW 18.79.260 and 2012 c 164 s 407, 2012 c 13 s 3, and 2012 c 10 s 37 are each reenacted and amended to read as follows:
- 37 (1) A registered nurse under his or her license may perform for 38 compensation nursing care, as that term is usually understood, to 39 individuals with illnesses, injuries, or disabilities.

р. 11 НВ 2967

- (2) A registered nurse may, at or under the general direction of a licensed physician and surgeon, dentist, osteopathic physician and surgeon, naturopathic physician, optometrist, podiatric physician and surgeon, physician assistant, prescribing psychologist, osteopathic physician assistant, advanced registered nurse practitioner, or midwife acting within the scope of his or her license, administer medications, treatments, tests, and inoculations, whether or not the severing or penetrating of tissues is involved and whether or not a degree of independent judgment and skill is required. Such direction must be for acts which are within the scope of registered nursing practice.
- (3) A registered nurse may delegate tasks of nursing care to other individuals where the registered nurse determines that it is in the best interest of the patient.
  - (a) The delegating nurse shall:

- 16 (i) Determine the competency of the individual to perform the 17 tasks;
  - (ii) Evaluate the appropriateness of the delegation;
- 19 (iii) Supervise the actions of the person performing the 20 delegated task; and
- 21 (iv) Delegate only those tasks that are within the registered 22 nurse's scope of practice.
  - (b) A registered nurse, working for a home health or hospice agency regulated under chapter 70.127 RCW, may delegate the application, instillation, or insertion of medications to a registered or certified nursing assistant under a plan of care.
  - (c) Except as authorized in (b) or (e) of this subsection, a registered nurse may not delegate the administration of medications. Except as authorized in (e) of this subsection, a registered nurse may not delegate acts requiring substantial skill, and may not delegate piercing or severing of tissues. Acts that require nursing judgment shall not be delegated.
  - (d) No person may coerce a nurse into compromising patient safety by requiring the nurse to delegate if the nurse determines that it is inappropriate to do so. Nurses shall not be subject to any employer reprisal or disciplinary action by the nursing care quality assurance commission for refusing to delegate tasks or refusing to provide the required training for delegation if the nurse determines delegation may compromise patient safety.

p. 12 HB 2967

(e) For delegation in community-based care settings or in-home care settings, a registered nurse may delegate nursing care tasks only to registered or certified nursing assistants or home care aides certified under chapter 18.88B RCW. Simple care tasks such as blood pressure monitoring, personal care service, diabetic insulin device set up, verbal verification of insulin dosage for sight-impaired individuals, or other tasks as defined by the nursing care quality assurance commission are exempted from this requirement.

- (i) "Community-based care settings" includes: Community residential programs for people with developmental disabilities, certified by the department of social and health services under chapter 71A.12 RCW; adult family homes licensed under chapter 70.128 RCW; and assisted living facilities licensed under chapter 18.20 RCW. Community-based care settings do not include acute care or skilled nursing facilities.
- (ii) "In-home care settings" include an individual's place of temporary or permanent residence, but does not include acute care or skilled nursing facilities, and does not include community-based care settings as defined in (e)(i) of this subsection.
- (iii) Delegation of nursing care tasks in community-based care settings and in-home care settings is only allowed for individuals who have a stable and predictable condition. "Stable and predictable condition" means a situation in which the individual's clinical and behavioral status is known and does not require the frequent presence and evaluation of a registered nurse.
- (iv) The determination of the appropriateness of delegation of a nursing task is at the discretion of the registered nurse. Other than delegation of the administration of insulin by injection for the purpose of caring for individuals with diabetes, the administration of medications by injection, sterile procedures, and central line maintenance may never be delegated.
- (v) When delegating insulin injections under this section, the registered nurse delegator must instruct the individual regarding proper injection procedures and the use of insulin, demonstrate proper injection procedures, and must supervise and evaluate the individual performing the delegated task weekly during the first four weeks of delegation of insulin injections. If the registered nurse delegator determines that the individual is competent to perform the injection properly and safely, supervision and evaluation shall occur at least every ninety days thereafter.

р. 13

(vi)(A) The registered nurse shall verify that the nursing assistant or home care aide, as the case may be, has completed the required core nurse delegation training required in chapter 18.88A or 18.88B RCW prior to authorizing delegation.

1

2

3

4

5

6

7

8

9

10

1112

13

14

1516

17

18

19

32

33

- (B) Before commencing any specific nursing tasks authorized to be delegated in this section, a home care aide must be certified pursuant to chapter 18.88B RCW and must comply with RCW 18.88B.070.
- (vii) The nurse is accountable for his or her own individual actions in the delegation process. Nurses acting within the protocols of their delegation authority are immune from liability for any action performed in the course of their delegation duties.
- (viii) Nursing task delegation protocols are not intended to regulate the settings in which delegation may occur, but are intended to ensure that nursing care services have a consistent standard of practice upon which the public and the profession may rely, and to safeguard the authority of the nurse to make independent professional decisions regarding the delegation of a task.
- (f) The nursing care quality assurance commission may adopt rules to implement this section.
- 20 (4) Only a person licensed as a registered nurse may instruct 21 nurses in technical subjects pertaining to nursing.
- 22 (5) Only a person licensed as a registered nurse may hold herself 23 or himself out to the public or designate herself or himself as a 24 registered nurse.
- 25 **Sec. 9.** RCW 69.50.101 and 2019 c 394 s 9, 2019 c 158 s 12, and 26 2019 c 55 s 11 are each reenacted and amended to read as follows:
- The definitions in this section apply throughout this chapter unless the context clearly requires otherwise.
- 29 (a) "Administer" means to apply a controlled substance, whether 30 by injection, inhalation, ingestion, or any other means, directly to 31 the body of a patient or research subject by:
  - (1) a practitioner authorized to prescribe (or, by the practitioner's authorized agent); or
- 34 (2) the patient or research subject at the direction and in the 35 presence of the practitioner.
- 36 (b) "Agent" means an authorized person who acts on behalf of or 37 at the direction of a manufacturer, distributor, or dispenser. It 38 does not include a common or contract carrier, public 39 warehouseperson, or employee of the carrier or warehouseperson.

p. 14 HB 2967

- 1 (c) "Board" means the Washington state liquor and cannabis board.
- (d) "CBD concentration" has the meaning provided in RCW 2 3 69.51A.010.
- (e) "CBD product" means any product containing or consisting of 4 cannabidiol.
  - (f) "Commission" means the pharmacy quality assurance commission.
  - (g) "Controlled substance" means a drug, substance, or immediate precursor included in Schedules I through V as set forth in federal or state laws, or federal or commission rules, but does not include hemp or industrial hemp as defined in RCW 15.140.020.
  - (h)(1) "Controlled substance analog" means a substance the chemical structure of which is substantially similar to the chemical structure of a controlled substance in Schedule I or II and:
  - (i) that has a stimulant, depressant, or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance included in Schedule I or II; or
  - (ii) with respect to a particular individual, that the individual represents or intends to have a stimulant, depressant, or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance included in Schedule I or II.
    - (2) The term does not include:
    - (i) a controlled substance;

6 7

8

9

10 11

12

13

14

15 16

17

18

19

20

21 22

23

24 25

28

29

30 31

32

39

- 26 (ii) a substance for which there is an approved new drug 27 application;
  - (iii) a substance with respect to which an exemption is in effect for investigational use by a particular person under Section 505 of the federal food, drug, and cosmetic act, 21 U.S.C. Sec. 355, or chapter 69.77 RCW to the extent conduct with respect to the substance is pursuant to the exemption; or
- 33 (iv) any substance to the extent not intended for human consumption before an exemption takes effect with respect to the 34 35 substance.
- (i) "Deliver" or "delivery" means the actual or constructive 36 transfer from one person to another of a substance, whether or not 37 38 there is an agency relationship.
  - (j) "Department" means the department of health.

p. 15 HB 2967

- 1 (k) "Designated provider" has the meaning provided in RCW 2 69.51A.010.
  - (1) "Dispense" means the interpretation of a prescription or order for a controlled substance and, pursuant to that prescription or order, the proper selection, measuring, compounding, labeling, or packaging necessary to prepare that prescription or order for delivery.
    - (m) "Dispenser" means a practitioner who dispenses.

4

5

7

8

11

12

1314

1516

17

18

19

20

2122

23

2425

26

2728

29

30

34

3536

37

- 9 (n) "Distribute" means to deliver other than by administering or dispensing a controlled substance.
  - (o) "Distributor" means a person who distributes.
  - (p) "Drug" means (1) a controlled substance recognized as a drug in the official United States pharmacopoeia/national formulary or the official homeopathic pharmacopoeia of the United States, or any supplement to them; (2) controlled substances intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in individuals or animals; (3) controlled substances (other than food) intended to affect the structure or any function of the body of individuals or animals; and (4) controlled substances intended for use as a component of any article specified in (1), (2), or (3) of this subsection. The term does not include devices or their components, parts, or accessories.
  - (q) "Drug enforcement administration" means the drug enforcement administration in the United States Department of Justice, or its successor agency.
  - (r) "Electronic communication of prescription information" means the transmission of a prescription or refill authorization for a drug of a practitioner using computer systems. The term does not include a prescription or refill authorization verbally transmitted by telephone nor a facsimile manually signed by the practitioner.
- 31 (s) "Immature plant or clone" means a plant or clone that has no 32 flowers, is less than twelve inches in height, and is less than 33 twelve inches in diameter.
  - (t) "Immediate precursor" means a substance:
  - (1) that the commission has found to be and by rule designates as being the principal compound commonly used, or produced primarily for use, in the manufacture of a controlled substance;
- 38 (2) that is an immediate chemical intermediary used or likely to 39 be used in the manufacture of a controlled substance; and

p. 16 HB 2967

1 (3) the control of which is necessary to prevent, curtail, or limit the manufacture of the controlled substance.

- (u) "Isomer" means an optical isomer, but in subsection (gg) (5) of this section, RCW 69.50.204(a) (12) and (34), and 69.50.206(b) (4), the term includes any geometrical isomer; in RCW 69.50.204(a) (8) and (42), and 69.50.210(c) the term includes any positional isomer; and in RCW 69.50.204(a) (35), 69.50.204(c), and 69.50.208(a) the term includes any positional or geometric isomer.
- (v) "Lot" means a definite quantity of marijuana, marijuana concentrates, useable marijuana, or marijuana-infused product identified by a lot number, every portion or package of which is uniform within recognized tolerances for the factors that appear in the labeling.
- (w) "Lot number" must identify the licensee by business or trade name and Washington state unified business identifier number, and the date of harvest or processing for each lot of marijuana, marijuana concentrates, useable marijuana, or marijuana-infused product.
- (x) "Manufacture" means the production, preparation, propagation, compounding, conversion, or processing of a controlled substance, either directly or indirectly or by extraction from substances of natural origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, and includes any packaging or repackaging of the substance or labeling or relabeling of its container. The term does not include the preparation, compounding, packaging, repackaging, labeling, or relabeling of a controlled substance:
- (1) by a practitioner as an incident to the practitioner's administering or dispensing of a controlled substance in the course of the practitioner's professional practice; or
- (2) by a practitioner, or by the practitioner's authorized agent under the practitioner's supervision, for the purpose of, or as an incident to, research, teaching, or chemical analysis and not for sale.
- (y) "Marijuana" or "marihuana" means all parts of the plant Cannabis, whether growing or not, with a THC concentration greater than 0.3 percent on a dry weight basis; the seeds thereof; the resin extracted from any part of the plant; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seeds or resin. The term does not include:

p. 17 HB 2967

(1) The mature stalks of the plant, fiber produced from the stalks, oil or cake made from the seeds of the plant, any other compound, manufacture, salt, derivative, mixture, or preparation of the mature stalks (except the resin extracted therefrom), fiber, oil, or cake, or the sterilized seed of the plant which is incapable of germination; or

- (2) Hemp or industrial hemp as defined in RCW 15.140.020, seeds used for licensed hemp production under chapter 15.140 RCW.
- (z) "Marijuana concentrates" means products consisting wholly or in part of the resin extracted from any part of the plant *Cannabis* and having a THC concentration greater than ten percent.
- (aa) "Marijuana processor" means a person licensed by the state liquor and cannabis board to process marijuana into marijuana concentrates, useable marijuana, and marijuana-infused products, package and label marijuana concentrates, useable marijuana, and marijuana-infused products for sale in retail outlets, and sell marijuana concentrates, useable marijuana, and marijuana-infused products at wholesale to marijuana retailers.
- (bb) "Marijuana producer" means a person licensed by the state liquor and cannabis board to produce and sell marijuana at wholesale to marijuana processors and other marijuana producers.
- (cc) "Marijuana products" means useable marijuana, marijuana concentrates, and marijuana-infused products as defined in this section.
- (dd) "Marijuana researcher" means a person licensed by the state liquor and cannabis board to produce, process, and possess marijuana for the purposes of conducting research on marijuana and marijuanaderived drug products.
- (ee) "Marijuana retailer" means a person licensed by the state liquor and cannabis board to sell marijuana concentrates, useable marijuana, and marijuana-infused products in a retail outlet.
- (ff) "Marijuana-infused products" means products that contain marijuana or marijuana extracts, are intended for human use, are derived from marijuana as defined in subsection (y) of this section, and have a THC concentration no greater than ten percent. The term "marijuana-infused products" does not include either useable marijuana or marijuana concentrates.
- 38 (gg) "Narcotic drug" means any of the following, whether produced 39 directly or indirectly by extraction from substances of vegetable

р. 18 НВ 2967

origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:

- (1) Opium, opium derivative, and any derivative of opium or opium derivative, including their salts, isomers, and salts of isomers, whenever the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation. The term does not include the isoguinoline alkaloids of opium.
- (2) Synthetic opiate and any derivative of synthetic opiate, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation.
  - (3) Poppy straw and concentrate of poppy straw.
- 14 (4) Coca leaves, except coca leaves and extracts of coca leaves 15 from which cocaine, ecgonine, and derivatives or ecgonine or their 16 salts have been removed.
  - (5) Cocaine, or any salt, isomer, or salt of isomer thereof.
  - (6) Cocaine base.

1

2

3

4

5

7

8

9

10 11

12

13

17

18

21

22

2425

26

27

2829

30 31

32

33

34

39

- 19 (7) Ecgonine, or any derivative, salt, isomer, or salt of isomer 20 thereof.
  - (8) Any compound, mixture, or preparation containing any quantity of any substance referred to in ((subparagraphs)) (1) through (7) of this subsection.
    - (hh) "Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability. The term includes opium, substances derived from opium (opium derivatives), and synthetic opiates. The term does not include, unless specifically designated as controlled under RCW 69.50.201, the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). The term includes the racemic and levorotatory forms of dextromethorphan.
  - (ii) "Opium poppy" means the plant of the species Papaver somniferum L., except its seeds.
- 35 (jj) "Person" means individual, corporation, business trust, 36 estate, trust, partnership, association, joint venture, government, 37 governmental subdivision or agency, or any other legal or commercial 38 entity.
  - (kk) "Plant" has the meaning provided in RCW 69.51A.010.

p. 19 HB 2967

(11) "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.

## (mm) "Practitioner" means:

1

2

3

2425

2627

2829

30 31

32

33

34

35

36 37

38

- (1) A physician under chapter 18.71 RCW; a physician assistant 4 under chapter 18.71A RCW; an osteopathic physician and surgeon under 5 6 chapter 18.57 RCW; an osteopathic physician assistant under chapter 18.57A RCW who is licensed under RCW 18.57A.020 subject to any 7 limitations in RCW 18.57A.040; an optometrist licensed under chapter 8 18.53 RCW who is certified by the optometry board under RCW 18.53.010 9 subject to any limitations in RCW 18.53.010; a dentist under chapter 10 11 18.32 RCW; a podiatric physician and surgeon under chapter 18.22 RCW; 12 a veterinarian under chapter 18.92 RCW; a registered nurse, advanced registered nurse practitioner, or licensed practical nurse under 13 chapter 18.79 RCW; a naturopathic physician under chapter 18.36A RCW 14 15 who is licensed under RCW 18.36A.030 subject to any limitations in 16 RCW 18.36A.040; a psychologist licensed under chapter 18.83 RCW and 17 certified as a prescribing psychologist under section 2 of this act; a pharmacist under chapter 18.64 RCW or a scientific investigator 18 under this chapter, licensed, registered or otherwise permitted 19 insofar as is consistent with those licensing laws to distribute, 20 21 dispense, conduct research with respect to or administer a controlled substance in the course of their professional practice or research in 22 23 this state.
  - (2) A pharmacy, hospital or other institution licensed, registered, or otherwise permitted to distribute, dispense, conduct research with respect to or to administer a controlled substance in the course of professional practice or research in this state.
  - (3) A physician licensed to practice medicine and surgery, a physician licensed to practice osteopathic medicine and surgery, a dentist licensed to practice dentistry, a podiatric physician and surgeon licensed to practice podiatric medicine and surgery, a licensed physician assistant or a licensed osteopathic physician assistant specifically approved to prescribe controlled substances by his or her state's medical commission or equivalent and his or her supervising physician, an advanced registered nurse practitioner licensed to prescribe controlled substances, or a veterinarian licensed to practice veterinary medicine in any state of the United States.
- 39 (nn) "Prescription" means an order for controlled substances 40 issued by a practitioner duly authorized by law or rule in the state

p. 20 HB 2967

- of Washington to prescribe controlled substances within the scope of his or her professional practice for a legitimate medical purpose.
- 3 (oo) "Production" includes the manufacturing, planting, 4 cultivating, growing, or harvesting of a controlled substance.
- 5 (pp) "Qualifying patient" has the meaning provided in RCW 6 69.51A.010.
- 7 (qq) "Recognition card" has the meaning provided in RCW 8 69.51A.010.
- 9 (rr) "Retail outlet" means a location licensed by the state 10 liquor and cannabis board for the retail sale of marijuana 11 concentrates, useable marijuana, and marijuana-infused products.
- 12 (ss) "Secretary" means the secretary of health or the secretary's designee.

1516

17

2425

26

2728

- (tt) "State," unless the context otherwise requires, means a state of the United States, the District of Columbia, the Commonwealth of Puerto Rico, or a territory or insular possession subject to the jurisdiction of the United States.
- 18 (uu) "THC concentration" means percent of delta-9
  19 tetrahydrocannabinol content per dry weight of any part of the plant
  20 Cannabis, or per volume or weight of marijuana product, or the
  21 combined percent of delta-9 tetrahydrocannabinol and
  22 tetrahydrocannabinolic acid in any part of the plant Cannabis
  23 regardless of moisture content.
  - (vv) "Ultimate user" means an individual who lawfully possesses a controlled substance for the individual's own use or for the use of a member of the individual's household or for administering to an animal owned by the individual or by a member of the individual's household.
- (ww) "Useable marijuana" means dried marijuana flowers. The term "useable marijuana" does not include either marijuana-infused products or marijuana concentrates.

--- END ---

p. 21 HB 2967